Telotristat etiprate - TerSera Therapeutics
Alternative Names: LP-778914; LX-1032; LX-1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; XermeloLatest Information Update: 28 Aug 2024
At a glance
- Originator Lexicon Pharmaceuticals
- Developer Ipsen; Lexicon Pharmaceuticals
- Class Amines; Anti-inflammatories; Antineoplastics; Chlorobenzenes; Fluorinated hydrocarbons; Propionic acids; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Tryptophan hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant carcinoid syndrome
- Phase II Neuroendocrine tumours
- No development reported Cholangiocarcinoma; Colorectal cancer; Liposarcoma
- Discontinued Biliary cancer; Ulcerative colitis
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Cholangiocarcinoma in USA
- 28 Aug 2024 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 28 Aug 2024 No recent reports of development identified for preclinical development in Liposarcoma in USA